Head-to-head · WeighScore
bmiMD vs Fitstry
By GLP-1 ScorecardUpdated
Score comparison
bmiMD has the higher recorded score — 79.2/100 to 61.5/100.
bmiMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | bmiMD | Fitstry |
|---|---|---|
| WeighScore | 79.2/100 | 61.5/100 |
| Grade | C+ | C |
| Site position | #29 | #329 |
| Semaglutide | $159/mo month-to-month ($119/mo equivalent with $1,428 prepaid for 12 months) | $179/mo (annual plan, plus a separate fee, compounded) |
| Tirzepatide | $249/mo month-to-month ($179/mo equivalent with $2,148 prepaid for 12 months) | $269/mo (annual plan, compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #29 · C+
Strengths
- Advertises the same price across prescribed doses for each selected injection plan
- Publishes compounded semaglutide and tirzepatide injection plans
- Every rung of both ladders is published with the total charge beside each per-month figure
- All 50 states
What to consider
- The pricing block opens on the 3-Month tab, so the figure a reader meets first is a commitment rate rather than a month
- The annual $119 and $179 monthly equivalents require $1,428 or $2,148 paid upfront for 12 months
- A struck-through $228.60 and $349.20 sit above the ladders under a standing LIMITED TIME label, with no published basis
- Neither the compounding pharmacy nor the prescribing group is named on the product pages
Site position #329 · C
Strengths
- Transparent pricing before you commit — compounded semaglutide from $179/mo, tirzepatide from $269/mo, oral GLP-1 from $209/mo (annual plan)
- Free screening with a one-time $99 program fee that is fully refunded if a clinician can't prescribe ('Approved, or Your $99 Back')
- Monthly price bundles a lab panel (CMP, A1c, lipids, TSH), unlimited clinician access, bi-weekly care coaching and a 24/7 Care Line
- Runs under Weightstry, LLC, a LegitScript-certified practice, with a named support email and phone
- Full compounded lineup — weekly injection, daily oral tablet and microdosing options
What to consider
- Month-to-month pricing is notably higher than the annual plan ($249 vs $179 semaglutide, $339 vs $269 tirzepatide)
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Framed for women 40+, and serves 49 states rather than all 50 (the excluded state isn't disclosed publicly)
- Works with state-licensed compounding pharmacies but doesn't name a specific pharmacy partner on the Fitstry page
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Featured provider
bmiMD
bmiMD scores 79.2/100 (C+). bmiMD publishes monthly and prepaid injection plans with advertised pricing that stays the same across prescribed doses; its lowest monthly equivalents require a year upfront.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.